Wednesday, September 20, 2017 10:01:47 AM
DJ Pfizer Files Antitrust Lawsuit Alleging J&J Thwarted Use of Biosimilar Rival to Remicade
By Jonathan D. Rockoff
Pfizer Inc. filed suit against Johnson & Johnson on Wednesday, alleging it has thwarted biosimilar competition to its arthritis drug Remicade by effectively preventing health insurers, hospitals and clinics from offering Pfizer's lower-priced copy.
The complaint, filed in federal court in Philadelphia, says J&J's "exclusionary contracts" have stopped hospitals and clinics from buying Pfizer's Inflectra biosimilar and health insurers from paying for prescriptions if they wanted rebates and other perks.
Pfizer has asked the federal district court to void the contracts and order J&J to pay damages compensating for lost sales.
The lawsuit is the first antitrust action to surface in the emerging market for biosimilars, after years of litigation over patents and timing of launches.
Biotech drugs, which are produced in living cells and typically infused or injected, have provided help to patients with conditions ranging from cancer to hepatitis C to multiple sclerosis. But they cost a lot, often more than $100,000 a year for a patient.
The 2010 health-care overhaul aimed to limit spending on drugs whose patents had expired by creating a regulatory framework for the approval of copies. Last April, Inflectra was among the first biosimilars to get the go-ahead. Pfizer began selling it at the end of the year.
A year's treatment on Remicade typically lists for $31,500, nearly $6,000 more than for Inflectra, according to SSR Health.
Write to Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com
(END) Dow Jones Newswires
September 20, 2017 09:11 ET (13:11 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Recent JNJ News
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/10/2024 09:14:19 PM
- Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 05/08/2024 08:30:00 PM
- Shockwave Medical Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/06/2024 08:05:00 PM
- Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization • Business Wire • 05/01/2024 10:30:00 AM
- Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) • Business Wire • 04/22/2024 08:30:00 PM
- Paramount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and More • IH Market News • 04/19/2024 11:31:22 AM
- US Index Futures See Gains, Oil Prices Dip • IH Market News • 04/17/2024 10:59:02 AM
- U.S. Stocks Finish Lackluster Session Narrowly Mixed • IH Market News • 04/16/2024 08:33:00 PM
- CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results • Business Wire • 04/16/2024 02:46:00 PM
- J&J’s Q1 2024 sales rise 2.3% to $21.4 billion • IH Market News • 04/16/2024 01:52:44 PM
- Dow Looks To Snap Six-Day Losing Streak As UnitedHealth Surges • IH Market News • 04/16/2024 01:09:47 PM
- U.S. Index Futures Signal Mixed Trading, Oil Prices Dip • IH Market News • 04/16/2024 11:19:33 AM
- Ericsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More News • IH Market News • 04/16/2024 11:18:19 AM
- Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2% • Business Wire • 04/16/2024 10:25:00 AM
- Johnson & Johnson Reports Q1 2024 Results • Business Wire • 04/16/2024 10:20:00 AM
- U.S. Stocks Extend Sell-Off As Treasury Yields Surge After Retail Sales Data • IH Market News • 04/15/2024 08:38:32 PM
- Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 04/08/2024 10:06:00 PM
- CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy • PR Newswire (US) • 04/06/2024 03:21:00 AM
- Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc. • PR Newswire (US) • 04/05/2024 06:55:00 PM
- Apple Terminates 614 Employees, Disney Unveils June Crackdown on Password Sharing, and More Updates • IH Market News • 04/05/2024 11:38:57 AM
- Johnson & Johnson to Acquire Shockwave Medical • Business Wire • 04/05/2024 10:31:00 AM
- Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation • Business Wire • 04/04/2024 10:01:00 PM
- Johnson & Johnson to Participate in the BofA Securities Health Care Conference • Business Wire • 04/02/2024 08:30:00 PM
- Walgreens Slashes Annual Profit Forecast; MillerKnoll Nosedives 17% on Bleak 4Q Outlook, and Latest News • IH Market News • 03/28/2024 01:48:04 PM
- GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News • IH Market News • 03/27/2024 10:54:47 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM